Skip to content

CRISPR Therapeutics

US · CRSP #2057 by market cap Listed 2016
39.10 +0.17 +0.44%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:54

Price chart

Pre-market 38.27 -1.70%
After-hours 39.50 +1.02%
Overnight 38.97 +0.10%
61.8938.9339.102026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on CRSP?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is -26.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 17.8% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Gross margin -215.0% Better than 0%
Operating margin -1,333.0% Better than 3%
Net margin -1,046.4% Better than 2%
Return on equity -30.2% Better than 13%
Return on invested capital -27.2% Better than 11%
Momentum D+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -34.3% Better than 14%
6-month return -22.4% Better than 25%
12-month return (ex latest month) -0.5% Better than 33%
Distance below 52-week high 38.4% Better than 30%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 13.3x Better than 96%
Debt to assets 9.1% Better than 71%
Interest coverage -1.8x Better than 20%
Free cash flow / net income 121.1% Better than 52%
Analyst View B+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 66.7% Better than 41%
Upside to average target 89.9% Better than 81%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -7.43%
1M -21.61%
3M -32.73%
6M -19.46%
YTD -25.44%
1Y -20.67%
3Y -45.83%
5Y -52.57%

Key statistics

Price & volume

Prev close
38.93
Open
38.18
Day range
38.15 - 40.17
Avg price
39.29
Volume
3.32M
Turnover
130.54M
Amplitude
5.19%
52-week range
38.15 - 63.45

Valuation

P/E
-6.04
P/E (TTM)
-8.27
P/B
2.30
EPS
-6.47
Net profit
-627.60M
Net assets
1.65B

Share structure

Market cap
3.79B
Float cap
3.77B
Shares out
97.00M
Float shares
96.49M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2016-10-19
52-week range 4% of range
38.15 63.45

38.4% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-33.00M net over the window

Short interest

Shares short
17.19M
As of
2026-10-30

Frequently asked questions

What is the current stock price of CRISPR Therapeutics (CRSP)?

CRISPR Therapeutics last traded at 39.10. This page shows a periodic quote snapshot. Check the displayed quote time.

What is CRISPR Therapeutics's market cap?

About 3.79B.

What is the P/E ratio of CRISPR Therapeutics?

The trailing twelve-month P/E is -8.27. The Valuation tab shows it against the stock's own five-year range.

Does CRISPR Therapeutics pay a dividend?

CRISPR Therapeutics does not currently pay a regular dividend.

Is CRISPR Therapeutics a buy according to analysts?

The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 74.27, which implies 89.9% upside from the current price. This is not investment advice.

What is CRISPR Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates CRISPR Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:54:43 · For reference only, not investment advice and not tailored to your situation.

CRISPR Therapeutics discussion 0 comments

Add a comment